| Reference |
|---|
Kumar P, Zhang X, Shaha R, Kschischo M, Dobbelstein M. Identification of antibody-resistant SARS-CoV-2 mutants via N4-Hydroxycytidine mutagenesis. Antiviral Res. 2024;231:106006 pubmed publisher |
Elste J, Cast N, Udawatte S, Adhikari K, Payen S, Verma S, et al. Co-Expression of Niemann-Pick Type C1-Like1 (NPC1L1) with ACE2 Receptor Synergistically Enhances SARS-CoV-2 Entry and Fusion. Biomedicines. 2024;12: pubmed publisher |
Mao L, Shaabani N, Zhang X, Jin C, Xu W, Argent C, et al. Olgotrelvir, a dual inhibitor of SARS-CoV-2 Mpro and cathepsin L, as a standalone antiviral oral intervention candidate for COVID-19. Med. 2024;5:42-61.e23 pubmed publisher |
Chen Y, Pr xe9 vost J, Ullah I, Roméro H, Lisi V, Tolbert W, et al. Molecular basis for antiviral activity of two pediatric neutralizing antibodies targeting SARS-CoV-2 Spike RBD. iScience. 2023;26:105783 pubmed publisher |
Cao X, Maruyama J, Zhou H, Fu Y, Kerwin L, Powers C, et al. Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodies. Sci Rep. 2022;12:15517 pubmed publisher |
Okura T, Shirato K, Kakizaki M, Sugimoto S, Matsuyama S, Tanaka T, et al. Hydrophobic Alpha-Helical Short Peptides in Overlapping Reading Frames of the Coronavirus Genome. Pathogens. 2022;11: pubmed publisher |
Wu T, Rabi S, Michaud W, Becerra D, Gilpin S, Mino Kenudson M, et al. Protease inhibitor Camostat Mesyalte blocks wild type SARS-CoV-2 and D614G viral entry in human engineered miniature lungs. Biomaterials. 2022;285:121509 pubmed publisher |
Izumida M, Kotani O, Hayashi H, Smith C, Fukuda T, Suga K, et al. Unique Mode of Antiviral Action of a Marine Alkaloid against Ebola Virus and SARS-CoV-2. Viruses. 2022;14: pubmed publisher |
Funari R, Fukuyama H, Shen A. Nanoplasmonic multiplex biosensing for COVID-19 vaccines. Biosens Bioelectron. 2022;208:114193 pubmed publisher |
Yang Z, Han Y, Ding S, Shi W, Zhou T, Finzi A, et al. SARS-CoV-2 Variants Increase Kinetic Stability of Open Spike Conformations as an Evolutionary Strategy. MBio. 2022;:e0322721 pubmed publisher |
Chiuppesi F, Nguyen V, Park Y, Contreras H, Karpinski V, Faircloth K, et al. Synthetic multiantigen MVA vaccine COH04S1 protects against SARS-CoV-2 in Syrian hamsters and non-human primates. NPJ Vaccines. 2022;7:7 pubmed publisher |
Peralta Garcia A, Torrens Fontanals M, Stępniewski T, Grau Expósito J, Perea D, Ayinampudi V, et al. Entrectinib-A SARS-CoV-2 Inhibitor in Human Lung Tissue (HLT) Cells. Int J Mol Sci. 2021;22: pubmed publisher |
Lassauniere R, Polacek C, Gram G, Frische A, Tingstedt J, Krüger M, et al. Preclinical evaluation of a candidate naked plasmid DNA vaccine against SARS-CoV-2. NPJ Vaccines. 2021;6:156 pubmed publisher |
Li J, Xu D, Wang L, Zhang M, Zhang G, Li E, et al. Glycyrrhizic Acid Inhibits SARS-CoV-2 Infection by Blocking Spike Protein-Mediated Cell Attachment. Molecules. 2021;26: pubmed publisher |
Muecksch F, Weisblum Y, Barnes C, Schmidt F, Schaefer Babajew D, Wang Z, et al. Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. Immunity. 2021;54:1853-1868.e7 pubmed publisher |
Kaku Y, Kuwata T, Zahid H, Hashiguchi T, Noda T, Kuramoto N, et al. Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19. Cell Rep. 2021;36:109385 pubmed publisher |
Postnikova O, Uppal S, Huang W, KANE M, Villasmil R, Rogozin I, et al. The Functional Consequences of the Novel Ribosomal Pausing Site in SARS-CoV-2 Spike Glycoprotein RNA. Int J Mol Sci. 2021;22: pubmed publisher |
Chen Y, Lear T, EVANKOVICH J, Larsen M, Lin B, Alfaras I, et al. A high-throughput screen for TMPRSS2 expression identifies FDA-approved compounds that can limit SARS-CoV-2 entry. Nat Commun. 2021;12:3907 pubmed publisher |
Harrington W, Trakhimets O, Andrade D, Dambrauskas N, Raappana A, Jiang Y, et al. Rapid decline of neutralizing antibodies is associated with decay of IgM in adults recovered from mild COVID-19. Cell Rep Med. 2021;2:100253 pubmed publisher |
Kim Y, Lee M, Lee S, Chung H, Kim K, Lee T, et al. Neutralizing Human Antibodies against Severe Acute Respiratory Syndrome Coronavirus 2 Isolated from a Human Synthetic Fab Phage Display Library. Int J Mol Sci. 2021;22: pubmed publisher |
Ozono S, Zhang Y, Ode H, Sano K, Tan T, Imai K, et al. SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced ACE2-binding affinity. Nat Commun. 2021;12:848 pubmed publisher |
Chiuppesi F, Salazar M, Contreras H, Nguyen V, Martinez J, Park Y, et al. Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform. Nat Commun. 2020;11:6121 pubmed publisher |
Lu M, Uchil P, Li W, Zheng D, Terry D, Gorman J, et al. Real-Time Conformational Dynamics of SARS-CoV-2 Spikes on Virus Particles. Cell Host Microbe. 2020;28:880-891.e8 pubmed publisher |
Wang S, Peng Y, Wang R, Jiao S, Wang M, Huang W, et al. Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys. Nat Commun. 2020;11:5752 pubmed publisher |
Lu M, Uchil P, Li W, Zheng D, Terry D, Gorman J, et al. Real-time conformational dynamics of SARS-CoV-2 spikes on virus particles. bioRxiv. 2020;: pubmed publisher |
Yi C, Sun X, Ye J, Ding L, Liu M, Yang Z, et al. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies. Cell Mol Immunol. 2020;17:621-630 pubmed publisher |
